drugset / Trial / NCT07183319
Circulating Tumor DNA Response In Urothelial Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this clinical trial is to evaluate the effectiveness of pembrolizumab monotherapy following 24 weeks of frontline pembrolizumab \& Enfortumab Vedotin (PEV) in patients with metastatic urothelial cancer (mUC).
Timeline
- Start
- 2026-01-19
- Primary completion
- 2028-03
- Completion
- 2029-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Enfortumab Vedotin | Other / unclassified | 1.25 mg/kg | — |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | — |
| Subject | Pembrolizumab | Monoclonal antibody | 400 mg | — |